UCB will build a 300 million euro bio-products plant with 150 additional workers

UCB recently completed a $2.5 billion autoimmune candidate drug deal, saying it believes more biopharmaceutical production is needed. To fill the gap, it will build a 300 million euro ($333 million) plant with 150 new employees.
The Belgian company said work on the facility would begin soon at its plant in Brene-al-Ude, Varon, Belgium. The plant is scheduled to open in 2024.
UCB says biotechnology plants are needed for future clinical development of monoclonal antibody therapies.
"Our pipeline towards large molecules requires us to invest more in mammalian technology development and manufacturing capabilities," Colston Lund-Jurgensen, head of supply and technology at UCB, said in a statement.
Related: UCB's $2.5 billion acquisition of Raby Alexis Solis' rival comes just two months after UCB moved to buy Ra Biotech Pharmaceuticals in Cambridge, Massachusetts. Through the acquisition, UCB will acquire Alexis Solis's third-stage rival, which analysts believe will lead to a sensational sale.
Rheumatoid arthritis candidates are concentrated in the daily, self-administration subdern C5 inhibitor, called zilucoplan, and are currently in phase 3 trials of severe muscle weakness.Severe muscle weakness is a long-term autoimmune neuromuscular disease that causes muscle weakness, especially affecting the face, and in more severe cases can extend to the arms, legs and neck, known as systemic muscular dystrophy. It can lead to difficulty swallowing, speaking and breathing, which in some cases can become severe - known as a muscle crisis - and require hospitalization. （cyy123.com）